Triptans and CGRP blockade – impact on the cranial vasculature
Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission an...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-017-0811-5 |
id |
doaj-2e80e884bd7c4e15b23017985431fbcd |
---|---|
record_format |
Article |
spelling |
doaj-2e80e884bd7c4e15b23017985431fbcd2020-11-24T22:07:55ZengBMCThe Journal of Headache and Pain1129-23691129-23772017-10-011811710.1186/s10194-017-0811-5Triptans and CGRP blockade – impact on the cranial vasculatureSilvia Benemei0Francesca Cortese1Alejandro Labastida-Ramírez2Francesca Marchese3Lanfranco Pellesi4Michele Romoli5Anne Luise Vollesen6Christian Lampl7Messoud Ashina8On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS)Health Sciences Department, University of Florence, and Headache Centre, Careggi University HospitalDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo PontinoDept Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical CenterChild Neuropsichiatry Unit, University of PalermoMedical Toxicology Headache and Drug Abuse Center, University of Modena and Reggio EmiliaNeurology Clinic, University Hospital of PerugiaDanish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medicl Sciences, University of CopenhagenDepartment of Neurogeriatric Medicine, Headache Medical Center LinzDanish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of CopenhagenAbstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.http://link.springer.com/article/10.1186/s10194-017-0811-5TriptansCalcitonin gene related peptide – CGRPAnti-CGRP (receptor) monoclonal antibodies – mAbsMiddle meningeal arteryMiddle cerebral arteriesMigraine models |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Silvia Benemei Francesca Cortese Alejandro Labastida-Ramírez Francesca Marchese Lanfranco Pellesi Michele Romoli Anne Luise Vollesen Christian Lampl Messoud Ashina On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS) |
spellingShingle |
Silvia Benemei Francesca Cortese Alejandro Labastida-Ramírez Francesca Marchese Lanfranco Pellesi Michele Romoli Anne Luise Vollesen Christian Lampl Messoud Ashina On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS) Triptans and CGRP blockade – impact on the cranial vasculature The Journal of Headache and Pain Triptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models |
author_facet |
Silvia Benemei Francesca Cortese Alejandro Labastida-Ramírez Francesca Marchese Lanfranco Pellesi Michele Romoli Anne Luise Vollesen Christian Lampl Messoud Ashina On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS) |
author_sort |
Silvia Benemei |
title |
Triptans and CGRP blockade – impact on the cranial vasculature |
title_short |
Triptans and CGRP blockade – impact on the cranial vasculature |
title_full |
Triptans and CGRP blockade – impact on the cranial vasculature |
title_fullStr |
Triptans and CGRP blockade – impact on the cranial vasculature |
title_full_unstemmed |
Triptans and CGRP blockade – impact on the cranial vasculature |
title_sort |
triptans and cgrp blockade – impact on the cranial vasculature |
publisher |
BMC |
series |
The Journal of Headache and Pain |
issn |
1129-2369 1129-2377 |
publishDate |
2017-10-01 |
description |
Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment. |
topic |
Triptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models |
url |
http://link.springer.com/article/10.1186/s10194-017-0811-5 |
work_keys_str_mv |
AT silviabenemei triptansandcgrpblockadeimpactonthecranialvasculature AT francescacortese triptansandcgrpblockadeimpactonthecranialvasculature AT alejandrolabastidaramirez triptansandcgrpblockadeimpactonthecranialvasculature AT francescamarchese triptansandcgrpblockadeimpactonthecranialvasculature AT lanfrancopellesi triptansandcgrpblockadeimpactonthecranialvasculature AT micheleromoli triptansandcgrpblockadeimpactonthecranialvasculature AT anneluisevollesen triptansandcgrpblockadeimpactonthecranialvasculature AT christianlampl triptansandcgrpblockadeimpactonthecranialvasculature AT messoudashina triptansandcgrpblockadeimpactonthecranialvasculature AT onbehalfoftheschoolofadvancedstudiesoftheeuropeanheadachefederationehfsas triptansandcgrpblockadeimpactonthecranialvasculature |
_version_ |
1725818611299254272 |